Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors as potential antituberculotics: development in the past decade.

scientific article

Mycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors as potential antituberculotics: development in the past decade. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.3109/14756366.2014.959512
P698PubMed publication ID25383419

P50authorOndrej HolasQ59661895
Martin DoležalQ63663861
Pavel OndrejčekQ85935445
P2093author name stringMartin Dolezal
Ondrej Holas
Pavel Ondrejcek
P2860cites workEnoyl acyl carrier protein reductase inhibitors: a patent review (2006 - 2010).Q37886187
Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds.Q37979307
Metabolism of the antituberculosis drug ethionamideQ38065214
Synthesis, biological activity, and X-ray crystal structural analysis of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 1: 4'-substituted triclosan derivatives.Q40384446
Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosisQ42708829
Chemical synthesis and biological evaluation of triazole derivatives as inhibitors of InhA and antituberculosis agents.Q42719254
Dithiocarbamates strongly inhibit the β-class carbonic anhydrases from Mycobacterium tuberculosisQ44803551
Inhibition of the β-class carbonic anhydrases from Mycobacterium tuberculosis with carboxylic acidsQ44841721
Structural basis for the variation in triclosan affinity to enoyl reductasesQ45069470
The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of actionQ47215316
Dihalogenated sulfanilamides and benzolamides are effective inhibitors of the three β-class carbonic anhydrases fromMycobacterium tuberculosisQ58863161
The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistanceQ24631332
Crystal structure of the Mycobacterium tuberculosis enoyl-ACP reductase, InhA, in complex with NAD+ and a C16 fatty acyl substrateQ27618301
Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosanQ27619680
Targeting tuberculosis and malaria through inhibition of Enoyl reductase: compound activity and structural dataQ27640586
Inhibition of the Mycobacterium tuberculosis enoyl acyl carrier protein reductase InhA by arylamidesQ27647576
Triclosan Derivatives: Towards Potent Inhibitors of Drug-Sensitive and Drug-ResistantMycobacterium tuberculosisQ27653366
Slow-Onset Inhibition of the FabI Enoyl Reductase from Francisella tularensis : Residence Time and in Vivo ActivityQ27653711
A Slow, Tight Binding Inhibitor of InhA, the Enoyl-Acyl Carrier Protein Reductase from Mycobacterium tuberculosisQ27660104
Time-Dependent Diaryl Ether Inhibitors of InhA: Structure-Activity Relationship Studies of Enzyme Inhibition, Antibacterial Activity, and in vivo EfficacyQ27682088
Methyl-thiazoles: a novel mode of inhibition with the potential to develop novel inhibitors targeting InhA in Mycobacterium tuberculosisQ27687048
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsQ27861111
Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South AfricaQ28272340
Triclosan targets lipid synthesisQ28279853
Mycolic acids: structure, biosynthesis and physiological functionsQ28289888
Signature gene expression profiles discriminate between isoniazid-, thiolactomycin-, and triclosan-treated Mycobacterium tuberculosisQ28487562
Pyrrolidine carboxamides as a novel class of inhibitors of enoyl acyl carrier protein reductase from Mycobacterium tuberculosisQ33260049
Targeting fatty acid biosynthesis for the development of novel chemotherapeutics against Mycobacterium tuberculosis: evaluation of A-ring-modified diphenyl ethers as high-affinity InhA inhibitorsQ33292548
Novel inhibitors of InhA efficiently kill Mycobacterium tuberculosis under aerobic and anaerobic conditions.Q33917913
Drug-target residence time: critical information for lead optimization.Q34054343
Discovery of new inhibitors of Mycobacterium tuberculosis InhA enzyme using virtual screening and a 3D-pharmacophore-based approach.Q34867906
Improving outcomes for multidrug-resistant tuberculosis: aggressive regimens prevent treatment failure and deathQ35008349
Drug-target residence time and its implications for lead optimizationQ36556505
Development of modern InhA inhibitors to combat drug resistant strains of Mycobacterium tuberculosisQ36754701
Synthesis and in vitro antimycobacterial activity of B-ring modified diaryl ether InhA inhibitorsQ36800124
Diversity in enoyl-acyl carrier protein reductasesQ37371673
P433issue4
P407language of work or nameEnglishQ1860
P921main subjectMycobacterium tuberculosisQ130971
P304page(s)629-648
P577publication date2014-11-10
P1433published inJournal of Enzyme Inhibition and Medicinal ChemistryQ15708877
P1476titleMycobacterium tuberculosis enoyl-acyl carrier protein reductase inhibitors as potential antituberculotics: development in the past decade
P478volume30

Reverse relations

cites work (P2860)
Q49915173Antitubercular activity of 1,2,3-triazolyl fatty acid derivatives
Q35892439Design, development, drug-likeness, and molecular docking studies of novel piperidin-4-imine derivatives as antitubercular agents
Q38892242Enoyl acyl carrier protein reductase inhibitors: an updated patent review (2011 - 2015).
Q38547127Recently disclosed chemical entities as potential candidates for management of tuberculosis

Search more.